Abstracts Archive - Page 1825 of 2425 - ACR Meeting Abstracts

Abstract Number: 2040 • 2015 ACR/ARHP Annual Meeting
T Follicular Helper like CD4+CXCR5+pd-1+ Cells and T Follicular Helper like Type 2 Cells Subsets Are Increased in IgG4-Related Disease Patients
Aurélie Grados¹, Mikael Ebbo¹, Christelle Piperoglou², Matthieu Groh³, Alexis Regent⁴, Maxime Samson⁵, Benjamin Terrier⁶, Nathalie Morel⁷, Sylvain Audia⁵, Francois Maurier⁸, Julie Graveleau⁹, Mohamed Hamidou¹⁰, Amandine Forestier¹¹, Sylvain Palat¹², Emanuelle Bernit¹, Gilles Kaplanski¹³, Frederique Retornaz¹⁴, Bernard Bonotte¹⁵, Catherine Farnarier¹⁶, Jean-Robert Harle¹⁷, Nathalie Costedoat-Chalumeau⁷, Frederic Vely¹⁸ and Nicolas Schleinitz¹, ¹Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ²Immunology, CIML, AP-HM, Marseille, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Service de médecine interne, Hôpital Cochin, Paris, France, ⁵Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁸Medecine Interne, Metz, France, ⁹Medecine Interne Hotel Dieu Nantes, Nantes, France, ¹⁰Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹¹Internal Medicine, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France, ¹²Service de Medecine Interne, CHU limoges, Limoges, France, ¹³Internal Medicine hopital conception, Aix-Marseille Université, Marseille, France, ¹⁴Conseil General 13 cellule recherche, Marseille, France, ¹⁵Department of Internal medicine and Clinicla Immunology Dijon University Hospital, Dijon, France, ¹⁶Laboratoire d'immunologie, Hopital de la Conception, Marseille, France, ¹⁷Internal Medicine, Aix-Marseille Université, APHM, Marseille, France, ¹⁸CIML, Laboratoire d'Immunologie Conception AP-HM, Aix-Marseille université, Marseille, France
Background/Purpose: IgG4 related disease (IgG4-RD) is associated with characteristic pathological changes including lymphoplasmocytic infiltration with abundant IgG4 positive plasma cells, storiform fibrosis and obliterative phlebitis.…
Abstract Number: 2041 • 2015 ACR/ARHP Annual Meeting
Baseline Clinical and Laboratory Features of IgG4-Related Disease: Retrospective Japanese Multicenter Study of 333 Cases
Kazunori Yamada¹, Motohisa Yamamoto², Takako Saeki³, Ichiro Mizushima⁴, Shoko Matsui⁵, Hiroki Takahashi⁶, Mitsuhiro Kawano⁷ and Shigeyuki Kawa⁸, ¹Division of Rheumatology,, Kanazawa University Hospital, Kanazawa, Japan, ²First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, ³Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁴Kanazawa University Hospital, Kanazawa, Japan, ⁵Health Administration Center, University of Toyama, Toyama, Japan, ⁶epartment of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁷Division of Rheumatology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, ⁸Center for Health, Safety and Environmental Management, Shinshu University, Matsumoto, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a widely recognized systemic inflammatory disorder. However, owing to its extremely diverse clinical picture, each clinician encounters a clinically distinct…
Abstract Number: 2042 • 2015 ACR/ARHP Annual Meeting
Pancreatitis Subtypes Survey in 852 Childhood-Onset Systemic Lupus Erythematosus Patients: A Multicenter Cohort
Victor L Marques¹, Natali W. Gormezano¹, Eloisa Bonfá², Nadia E Aikawa³, Maria Teresa Terreri^4,5, Rosa M R Pereira⁶, Claudia Saad-Magalhães⁷, Andressa Guariento⁸, Simone Appenzeller⁹, Virgínia Ferriani¹⁰, Cássia M. Barbosa¹¹, Valéria C. Ramos¹², Simone Lotufo¹³ and Clovis A Silva³, ¹Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, ⁵Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, ⁶Rheumatology, Faculdade de Medicina da USP, São Paulo, Brazil, ⁷Brazil, Brazil, Brazil, ⁸Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁹Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil, ¹⁰Department of Pediatrics School of Medicine of Ribeirão Preto, University of São Paulo (USP-RP), Ribeirão Preto, Brazil, ¹¹Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹²Pediatric Rheumatology Unit, Pontifical Catholic University of Sorocaba, São Paulo, Brazil, ¹³Pediatric Rheumatology Unit, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil
Background/Purpose: Pancreatitis is uncommon and a life-threatening SLE manifestation in childhood-onset systemic lupus erythematosus (c-SLE) and it has been restricted to case reports or case…
Abstract Number: 2043 • 2015 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Have High Sensitivity and Specificity in Childhood-Onset Systemic Lupus Erythematosus and Juvenile Idiopathic Arthritis
Anca Askanase¹, Joyce Hui-Yuen², John Conklin³, Derren Barken⁴, Tyler O'Malley⁵, Xiao Qing Li⁶, Liza Mariel Bermudez², Andrew Eichenfield⁷, Amy J. Starr⁸, Lisa F. Imundo^9,10 and Thierry Dervieux¹¹, ¹Columbia University College of Physicians & Surgeons, New York, NY, ²Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA, ⁶Adult Rheumatology, Columbia University Medical Center, New York, NY, ⁷Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁸Columbia University Medical Center, New York, NY, ⁹Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ¹⁰New York Presbyterian Hospitsl, Columbia University, New York, NY, ¹¹Research and Development, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CBCAPS) have been demonstrated to be sensitive and…
Abstract Number: 2044 • 2015 ACR/ARHP Annual Meeting
Axonal Dysfunction in Childhood-Onset Systemic Lupus Erythematosus. Association with Neuropsychiatric Manifestations and Disease Activity
Renan Frittoli¹, Mariana Postal², Karina Pelicari², Nailu Sinicato³, Aline Tamires Lapa⁴, Fernando Peres¹, Fernando Cendes⁵, Roberto Marini Sr.⁶, Gabriela Castellano⁷, Leticia Rittner⁸ and Simone Appenzeller², ¹State University of Campinas, Campinas, Brazil, ²Medicine, State University of Campinas, Campinas, Brazil, ³pEDIATRICS, State University of Campinas, Campinas, Brazil, ⁴Rua Alexandre Fleming, Fcm09-Baraogeraldo, Campinas, Brazil, ⁵Neurology, State University of Campinas, Campinas, Brazil, ⁶Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁷Medical Physics, State University of Campinas, Campinas, Brazil, ⁸Electrical Engineering, State University of Campinas, Campinas, Brazil
Background/Purpose: Involvement of the central nervous system is frequently observed in childhood-onset SLE patients (cSLE). Proton magnetic spectroscopy (1H-MRS) is an important non-invasive method of…
Abstract Number: 2045 • 2015 ACR/ARHP Annual Meeting
Cross-Validation of the Pediatric Automated Neuropsychological Assessment Metrics-Cognitive Performance Scores in the Screening of Neurocognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus
Jasmine Nguyen¹, Tricia Williams², Earl Silverman³ and Deborah M. Levy⁴, ¹Royal College of Surgeons in Ireland, Dublin, Ireland, ²Psychology, Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Neurocognitive impairment (NCI) is an important morbidity in childhood-onset systemic lupus erythematosus (cSLE); however, the gold standard formal neuropsychological assessment is difficult to access. Screening for…
Abstract Number: 2046 • 2015 ACR/ARHP Annual Meeting
Long-Term Outcomes in Cardiac Neonatal Lupus and Associated Risk Factors for Morbidity
Amit Saxena¹, Peter M. Izmirly¹, Sara Sahl¹, Deborah Friedman² and Jill P. Buyon³, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatric Cardiology, New York Medical College, Valhalla, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: All women with anti-Ro antibodies face the risk of cardiac neonatal lupus (cardiac NL), which presents as congenital heart block (CHB) and/or cardiomyopathy in…
Abstract Number: 2047 • 2015 ACR/ARHP Annual Meeting
A Randomised Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Effects on Microarchitecture Measured By HR-pQCT
Glauce Lima¹, Juliane Paupitz¹, Nadia E Aikawa², Jackeline Couto Alvarenga³, Eloisa Bonfá¹ and Rosa M R Pereira⁴, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Vitamin D has an important effect in bone quality and vitamin D deficiency in Juvenile-onset Systemic Lupus Erythematosus patients (JoSLE) may be associated with…
Abstract Number: 2048 • 2015 ACR/ARHP Annual Meeting
Hospitalization Trends of Rheumatoid Arthritis and Gout in the United States: A Crossroad
Sian Yik Lim¹, Na Lu¹, Mark Fisher¹, Amar Oza¹, Sharan K. Rai², Mariano E Menendez¹ and Hyon Choi¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Rheumatoid arthritis (RA) and gout are the two most common inflammatory arthritides in the US and beyond. As hospitalization for these conditions are known…
Abstract Number: 2049 • 2015 ACR/ARHP Annual Meeting
Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases
Huifeng Yun¹, Fenglong Xie², John Baddley³, Kevin L. Winthrop⁴, Lang Chen⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵University of Alabama at Bimingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The live herpes zoster (HZ) vaccine is effective in healthy older people to reduce the incidence and burden of HZ. Recent results from a…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2051 • 2015 ACR/ARHP Annual Meeting
Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards
Anja Strangfeld¹, Adrian Richter², Peter Herzer³, Karin Rockwitz⁴, Winfried Demary⁵, Martin Aringer⁶, Angela Zink⁷ and Joachim Listing⁸, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, München, Germany, ⁴Rheumatologic Practice, Goslar, Germany, ⁵Rheumatologist, Hildesheim, Germany, ⁶Rheumatology, Medicine III, University Clinical Center, Technical University Dresden, Dresden, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Interleukin-6 has a direct protective effect on intestinal cells. Although several cases of lower intestinal perforations (LIP) were reported in clinical trials of tocilizumab…
Abstract Number: 2052 • 2015 ACR/ARHP Annual Meeting
Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes
Karin Hellgren¹, Christer Sundström², Johan Askling³, Eva Baecklund⁴ and on behalf of the ARTIS study group, ¹Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden, ²Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden, ³Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden
Background/Purpose: The long-term lymphoma risk in patients with rheumatoid arthritis (RA) treated with biologic disease modifying anti-rheumatic drugs (bDMARDs) remains a concern. The aim of…
Abstract Number: 2053 • 2015 ACR/ARHP Annual Meeting
Adjustment of Skeletal Muscle Mass Estimates for the Extent of Adiposity Strengthens Relationships with Functional Outcomes in Rheumatoid Arthritis
Joshua Baker¹, Jon Giles², Mary Leonard³, David Weber⁴, Jin Long⁵, Erik Jorgenson⁶ and Patricia P. Katz⁷, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Stanford University, Palo Alto, CA, ⁴Rochester University, Rochester, NY, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, UCSF, SF, CA
Background/Purpose: Skeletal muscle loss in rheumatoid arthritis (RA) has been described in association with poor physical functioning. Greater adiposity is simultaneously associated with both greater…
Abstract Number: 2054 • 2015 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Stanley B. Cohen¹, Mark C. Genovese², Ernest H. Choy³, Fernando Perez-Ruiz⁴, Jose L. Pablos⁵, Nan Zhang⁶ and Primal Kaur⁷, ¹Metroplex Clinical Research Center, Dallas, TX, ²Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁴Servicio de Reumatología, Vizcaya, Spain, ⁵Instituto de Investigacion Hospital, Madrid, Spain, ⁶Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁷Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical comparisons indicates that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].